In February 2006, the ISCTM held this meeting by satellite on the NIMH initiative regarding treatment development for negative symptoms of schizophrenia. Participants discussed the conceptual objectives and implementation of the initiative to date, in addition to the epidemiology and long-term course of negative symptoms. Other topics included the identification and management of psychometric challenges to the assessment of negative symptoms, the neurobiology of negative symptoms, and the Food and Drug Administration's perspective on negative symptoms as a clinical target. The meeting allowed broad input from industry and regulatory officials in advance of finalizing the battery. For more information, please contact Dr. Mi Hillefors.